Compare PKX & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKX | BBIO |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 15.3B |
| IPO Year | 1998 | 2019 |
| Metric | PKX | BBIO |
|---|---|---|
| Price | $59.68 | $73.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 23 |
| Target Price | N/A | ★ $82.26 |
| AVG Volume (30 Days) | 158.1K | ★ 2.8M |
| Earning Date | 01-01-0001 | 05-22-2026 |
| Dividend Yield | ★ 2.35% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $5.89 | $88.86 |
| Revenue Next Year | $3.90 | $74.11 |
| P/E Ratio | $42.95 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $40.80 | $28.33 |
| 52 Week High | $71.35 | $84.94 |
| Indicator | PKX | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 39.80 | 58.38 |
| Support Level | $58.83 | $70.65 |
| Resistance Level | $61.24 | $79.56 |
| Average True Range (ATR) | 1.90 | 3.35 |
| MACD | -1.34 | 0.42 |
| Stochastic Oscillator | 15.49 | 86.03 |
POSCO Holdings Inc is a holding company and operates through its subsidiaries. The company operates across four distinct segments. The first segment is the Steel Segment, which includes the production and sale of steel products. The second segment is the Infrastructure Business, which is further divided into three operations. The Trading Segment comprises trading and natural resource development activities. The Construction Segment involves the planning, designing, and construction of industrial plants, civil engineering projects, and buildings. The Logistics and Others Segment. The third segment is the Secondary Battery Materials Segment, and the fourth segment is the Others Segment.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.